A multicenter, randomised, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients (CRLXA).

Aim

To demonstrate that serelaxin is superior to placebo in reducing cardiovascular death in acute heart failure patients during a follow-up period of 180 days.

Trial Design

A randomised, double blind, placebo-controlled trial.

Chief Investigator

Metra Marco and Teerlink John for the RLX030A2301

Local PI

Dr Alasdair Gray

Research Team

Dr Martin Denvir – Co PI
Dr James Dear – Co PI
Dr Kristin Haga – Investigator
Dr Alastair Moss – Investigator
Polly Black – Research Nurse
Kirsty Simpson – Research Nurse
Rachel O’Brien – Research Nurse
Julia Grahamslaw – Research Nurse

Eligibility criteria (summary of )

Patients who are admitted to hospital with acute heart failure, who have received IV diuretics and have a degree of impaired renal function.